Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT J BUYNAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1508977984
CMS profile
340544
Location
VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,547.31

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,577.83 6
Food and Beverage $969.48 15

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim International GmbH $1,595.00 13
Alnylam Pharmaceuticals Inc. $952.31 8

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT J BUYNAK

NPI 1508977984 · CMS profile ID 340544

Allopathic & Osteopathic Physicians / Internal Medicine

VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $2,547.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331053 CMS
Boehringer Ingelheim International GmbH $40.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331055 CMS
Boehringer Ingelheim International GmbH $258.2310/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331057 CMS
Boehringer Ingelheim International GmbH $117.1110/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331059 CMS
Boehringer Ingelheim International GmbH $40.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331061 CMS
Boehringer Ingelheim International GmbH $145.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331063 CMS
Boehringer Ingelheim International GmbH $40.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331065 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331067 CMS
Boehringer Ingelheim International GmbH $145.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331069 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331071 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017333561 CMS
Boehringer Ingelheim International GmbH $258.2310/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017333567 CMS
Boehringer Ingelheim International GmbH $351.4308/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017332783 CMS
Alnylam Pharmaceuticals Inc. $270.1001/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151427 CMS
Alnylam Pharmaceuticals Inc. $89.9901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151433 CMS
Alnylam Pharmaceuticals Inc. $71.3001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151439 CMS
Alnylam Pharmaceuticals Inc. $49.8301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151443 CMS
Alnylam Pharmaceuticals Inc. $44.9901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151449 CMS
Alnylam Pharmaceuticals Inc. $60.8101/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151453 CMS
Alnylam Pharmaceuticals Inc. $42.5601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151461 CMS
Alnylam Pharmaceuticals Inc. $322.7301/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006151465 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,627.38 35
PY2022 $1,515.77 9
PY2023 $2,547.31 21
PY2024 $2,804.68 27
PY2025 $2,542.53 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,038,550.53 603
PY2024 Principal investigator $5,031,915.33 601
PY2023 Recipient $906.71 2
PY2023 Principal investigator $4,138,599.32 2,384
PY2022 Recipient $3,104.59 10
PY2022 Principal investigator $5,204,363.35 1,133
PY2021 Principal investigator $3,348,948.64 610
PY2020 Recipient $1,489.26 13
PY2020 Principal investigator $1,938,354.41 292
PY2019 Recipient $658.79 10
PY2019 Principal investigator $1,439,149.33 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

601 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157090
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157092
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157094
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157096
Principal investigator 1 AstraZeneca Pharmaceuticals LP $690.62 12/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 1155802320
Principal investigator 1 ModernaTX, Inc. $40,185.00 12/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142768
Principal investigator 1 ModernaTX, Inc. $91,174.35 12/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142942
Principal investigator 1 ModernaTX, Inc. $44,313.70 12/20/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147184221
Principal investigator 1 Currax Pharmaceuticals LLC $962.00 12/19/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520143
Principal investigator 1 Currax Pharmaceuticals LLC $4,158.41 12/19/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089521308
Principal investigator 1 Novo Nordisk AS $2,200.00 12/19/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096772653
Principal investigator 1 ModernaTX, Inc. $260,870.00 12/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142722
Principal investigator 1 ModernaTX, Inc. $81.96 12/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180219
Principal investigator 1 ModernaTX, Inc. $132,702.65 12/17/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142910
Principal investigator 1 Novo Nordisk AS $13,561.52 12/12/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096861662
Principal investigator 1 ModernaTX, Inc. $68.30 12/11/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180217
Principal investigator 1 ModernaTX, Inc. $49.89 12/10/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147180215
Principal investigator 1 Novo Nordisk AS $1,154.00 12/10/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096798910
Principal investigator 1 ModernaTX, Inc. $27,358.75 12/04/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147184219
Principal investigator 1 ModernaTX, Inc. $4,000.00 12/02/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184215
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/02/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157086
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157088
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157098
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157100
Principal investigator 1 ModernaTX, Inc. $75.13 11/29/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180199
Principal investigator 1 ModernaTX, Inc. $587,670.00 11/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142514
Principal investigator 1 ModernaTX, Inc. $28,260.60 11/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142654
Principal investigator 1 ModernaTX, Inc. $500.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184191
Principal investigator 1 ModernaTX, Inc. $2,325.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184193
Principal investigator 1 ModernaTX, Inc. $3,300.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184195
Principal investigator 1 ModernaTX, Inc. $753.38 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184197
Principal investigator 1 ModernaTX, Inc. $5,000.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184199
Principal investigator 1 Currax Pharmaceuticals LLC $4,147.00 11/21/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519743
Principal investigator 1 ModernaTX, Inc. $16,919.00 11/21/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147184211
Principal investigator 1 ModernaTX, Inc. $68.30 11/15/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180197
Principal investigator 1 ModernaTX, Inc. $750.00 11/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184205
Principal investigator 1 ModernaTX, Inc. $1,800.00 11/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184207
Principal investigator 1 ModernaTX, Inc. $1,746.00 11/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184209
Principal investigator 1 Currax Pharmaceuticals LLC $8,856.34 11/14/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089521023
Principal investigator 1 Currax Pharmaceuticals LLC $2,200.00 11/14/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089521114
Principal investigator 1 PFIZER INC. $14,000.00 11/14/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1130987418
Principal investigator 1 ModernaTX, Inc. $5,505.16 11/08/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147184189
Principal investigator 1 ModernaTX, Inc. $7,000.00 11/08/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147184213
Principal investigator 1 PFIZER INC. $4,725.00 11/08/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1130987423
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/06/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184201
Principal investigator 1 ModernaTX, Inc. $2,700.00 11/06/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147184203
Principal investigator 1 ModernaTX, Inc. $5,054.40 11/01/2024 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147184187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157082
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157084
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157102
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157104
Principal investigator 1 Eli Lilly and Company $195.00 10/31/2024 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1137350367
Principal investigator 1 ModernaTX, Inc. $561.00 10/30/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147180175
Principal investigator 1 ModernaTX, Inc. $7,550.00 10/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142164
Principal investigator 1 ModernaTX, Inc. $6,650.00 10/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142166
Principal investigator 1 ModernaTX, Inc. $3,325.00 10/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142168
Principal investigator 1 Currax Pharmaceuticals LLC $1,605.50 10/24/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519819
Principal investigator 1 Currax Pharmaceuticals LLC $5,400.00 10/24/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520056
Principal investigator 1 Currax Pharmaceuticals LLC $7,700.00 10/24/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520794
Principal investigator 1 ModernaTX, Inc. $102.45 10/22/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180177
Principal investigator 1 Seqirus USA Inc $194.40 10/21/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123451247
Principal investigator 1 Seqirus USA Inc $3,794.85 10/21/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123451255
Principal investigator 1 ModernaTX, Inc. $40,394.00 10/16/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147135269
Principal investigator 1 ModernaTX, Inc. $99.78 10/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147180173
Principal investigator 1 PFIZER INC. $4,000.00 10/16/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1130993100
Principal investigator 1 ModernaTX, Inc. $6,800.00 10/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142322
Principal investigator 1 ModernaTX, Inc. $19,200.00 10/09/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147142134
Principal investigator 1 ModernaTX, Inc. $200.00 10/09/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147142232
Principal investigator 1 Eli Lilly and Company $204.52 10/08/2024 Non-covered Recipient Entity
MEHRDAD KEVIN ARIANI MD
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1137363067
Principal investigator 1 ModernaTX, Inc. $7,053.79 10/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147135197
Principal investigator 1 ModernaTX, Inc. $833.62 10/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147135209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156926
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156928
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157048
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157050
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157052
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157054
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157056
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157058
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157060
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157062
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157064
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157066
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157068
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157070
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157072
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157074
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157076
Principal investigator 1 ModernaTX, Inc. $5,000.00 09/30/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142100
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,450.00 09/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1110842419
Principal investigator 1 Currax Pharmaceuticals LLC $4,246.19 09/26/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520643
Principal investigator 1 ModernaTX, Inc. $49,333.80 09/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147134967
Principal investigator 1 ModernaTX, Inc. $11,502.56 09/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141970
Principal investigator 1 PFIZER INC. $10,360.00 09/25/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131018826
Principal investigator 1 Seqirus USA Inc $4,998.43 09/25/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450995
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,624.60 09/20/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1110836952
Principal investigator 1 ModernaTX, Inc. $3,917.22 09/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141936
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123449355
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450799
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450801
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450803
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450805
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450807
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450809
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450811
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450813
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450815
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450817
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450819
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450821
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450823
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450825
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450827
Principal investigator 1 Seqirus USA Inc $506.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450829
Principal investigator 1 Seqirus USA Inc $703.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450831
Principal investigator 1 Seqirus USA Inc $506.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450833
Principal investigator 1 Seqirus USA Inc $703.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450835
Principal investigator 1 Seqirus USA Inc $506.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450837
Principal investigator 1 Seqirus USA Inc $703.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450839
Principal investigator 1 Seqirus USA Inc $506.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450841
Principal investigator 1 Seqirus USA Inc $703.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450843
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450845
Principal investigator 1 Seqirus USA Inc $506.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450847
Principal investigator 1 Seqirus USA Inc $703.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450849
Principal investigator 1 Seqirus USA Inc $506.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450851
Principal investigator 1 Seqirus USA Inc $703.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450853
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450855
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450857
Principal investigator 1 Seqirus USA Inc $121.00 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123450859
Principal investigator 1 ModernaTX, Inc. $399.12 09/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180151
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/12/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141932
Principal investigator 1 ModernaTX, Inc. $5,054.40 09/11/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147134969
Principal investigator 1 Currax Pharmaceuticals LLC $975.00 09/05/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519540
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 09/04/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157326
Principal investigator 1 ModernaTX, Inc. $500.00 09/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141900
Principal investigator 1 PFIZER INC. $6,660.00 09/04/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131018820
Principal investigator 1 ModernaTX, Inc. $1,792.70 09/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147134971
Principal investigator 1 ModernaTX, Inc. $59,993.48 09/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141854
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156922
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156924
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157018
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157020
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157022
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157024
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157026
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157028
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157030
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157032
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157034
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157036
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157038
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157040
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157042
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157044
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157046
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,234.00 08/26/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1110845727
Principal investigator 1 Mylan Specialty L.P. $10,110.44 08/26/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407902
Principal investigator 1 ModernaTX, Inc. $598.68 08/20/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147180139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 08/14/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157334
Principal investigator 1 ModernaTX, Inc. $56,177.50 08/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147134641
Principal investigator 1 ModernaTX, Inc. $859.29 08/09/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134479
Principal investigator 1 ModernaTX, Inc. $236.25 08/09/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134489
Principal investigator 1 ModernaTX, Inc. $75.00 08/09/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134491
Principal investigator 1 ModernaTX, Inc. $5,000.00 08/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134493
Principal investigator 1 ModernaTX, Inc. $9,251.55 08/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134499
Principal investigator 1 ModernaTX, Inc. $18,954.00 08/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147134607
Principal investigator 1 Seqirus USA Inc $20,693.40 08/02/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123448915
Principal investigator 1 ModernaTX, Inc. $4,704.75 08/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147134377
Principal investigator 1 ModernaTX, Inc. $33,551.72 08/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147134439
Principal investigator 1 ModernaTX, Inc. $14,502.34 08/01/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141642
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156918
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156920
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156930
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156932
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156934
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156936
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156938
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156940
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156942
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156944
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156946
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156948
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156950
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156952
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156954
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156956
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156958
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156960
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121157078
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121157080
Principal investigator 1 Novo Nordisk AS $2,200.00 07/24/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096748375
Principal investigator 1 Novo Nordisk AS $13,561.52 07/24/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096796231
Principal investigator 1 Novo Nordisk AS $1,154.00 07/24/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096820853
Principal investigator 1 ModernaTX, Inc. $1,074.12 07/19/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134063
Principal investigator 1 Currax Pharmaceuticals LLC $24,200.00 07/18/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520277
Principal investigator 1 ModernaTX, Inc. $75,501.25 07/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147134155
Principal investigator 1 Seqirus USA Inc $1,088.00 07/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123448767
Principal investigator 1 Seqirus USA Inc $1,088.00 07/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123448803
Principal investigator 1 ModernaTX, Inc. $1,503.76 07/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147134043
Principal investigator 1 PFIZER INC. $41,877.80 06/29/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131067259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156878
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156880
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156882
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156884
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156886
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156888
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156890
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156892
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156894
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156896
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156898
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156900
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156902
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156904
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156906
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156908
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156910
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156912
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156914
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156916
Principal investigator 1 AstraZeneca Pharmaceuticals LP $54,668.40 06/26/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110840348
Principal investigator 1 ModernaTX, Inc. $8,438.85 06/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147133775
Principal investigator 1 ModernaTX, Inc. $1,263.60 06/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147133829
Principal investigator 1 ModernaTX, Inc. $72,770.00 06/20/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147133861
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447107
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447117
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447898
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447900
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447965
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447967
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447969
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447971
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447973
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447975
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447977
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447979
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447981
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447983
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447985
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447987
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447989
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447991
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447993
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447995
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447997
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447999
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448001
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448003
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448005
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448007
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448009
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448613
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448615
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448617
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448619
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448621
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448623
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448625
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448627
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448629
Principal investigator 1 Currax Pharmaceuticals LLC $1,950.00 06/13/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519368
Principal investigator 1 ModernaTX, Inc. $58,208.89 06/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147133655
Principal investigator 1 ModernaTX, Inc. $26,239.72 06/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147133657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156796
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156802
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156804
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156806
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156808
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156810
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156812
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156814
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156816
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156818
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156820
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156822
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156824
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156842
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156846
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156854
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156856
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156858
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156876
Principal investigator 1 ModernaTX, Inc. $47,517.97 05/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141392
Principal investigator 1 ModernaTX, Inc. $100.50 05/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147180137
Principal investigator 1 Novo Nordisk AS $9,792.00 05/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096832091
Principal investigator 1 ModernaTX, Inc. $13,783.05 05/29/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147133437
Principal investigator 1 ModernaTX, Inc. $129,036.45 05/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147133473
Principal investigator 1 Seqirus USA Inc $979.20 05/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447109
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,860.00 05/10/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089696559
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,111.32 05/08/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 1110846433
Principal investigator 1 Novo Nordisk AS $432.00 05/08/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096735490
Principal investigator 1 Novo Nordisk AS $2,739.96 05/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096731344
Principal investigator 1 Novo Nordisk AS $442.44 05/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096800122
Principal investigator 1 Novo Nordisk AS $432.00 05/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096824383
Principal investigator 1 Novo Nordisk AS $3,888.36 05/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096752367
Principal investigator 1 Novo Nordisk AS $1,738.08 05/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096874157
Principal investigator 1 Novo Nordisk AS $3,597.48 05/03/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096872379
Principal investigator 1 ModernaTX, Inc. $1,719.36 05/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141332
Principal investigator 1 Novo Nordisk AS $4,167.72 05/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096740338
Principal investigator 1 Novo Nordisk AS $4,656.60 05/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096813871
Principal investigator 1 Novo Nordisk AS $358.56 05/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096824062
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,229.00 05/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157142
Principal investigator 1 Novo Nordisk AS $5,019.48 05/01/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096853911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156794
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156798
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156800
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156826
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156828
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156830
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156832
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156834
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156836
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156838
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156840
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156844
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156848
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156850
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156860
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156862
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156864
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156866
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156868
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156870
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156872
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156874
Principal investigator 1 ModernaTX, Inc. $10,000.00 04/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147132821
Principal investigator 1 Currax Pharmaceuticals LLC $13,500.00 04/25/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519175
Principal investigator 1 SANOFI PASTEUR INC. $48,325.55 04/19/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128703324
Principal investigator 1 ModernaTX, Inc. $6,718.73 04/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147132921
Principal investigator 1 ModernaTX, Inc. $95,689.12 04/15/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147132973
Principal investigator 1 PFIZER INC. $20,000.00 04/13/2024 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131087767
Principal investigator 1 ModernaTX, Inc. $29,991.92 04/10/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147132891
Principal investigator 1 ModernaTX, Inc. $77,010.00 04/10/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147133123
Principal investigator 1 ModernaTX, Inc. $18,301.68 04/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147132865
Principal investigator 1 ModernaTX, Inc. $2,778.00 04/05/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147141138
Principal investigator 1 ModernaTX, Inc. $24,119.66 04/05/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141208
Principal investigator 1 ModernaTX, Inc. $84,498.40 04/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147133061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157144
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157146
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157148
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157150
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157152
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157154
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157156
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,237.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157158
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157160
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157162
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,121.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157164
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157168
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,121.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157170
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157172
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157174
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,121.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157176
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157178
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157180
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157182
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157184
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,121.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157186
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157188
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157190
Principal investigator 1 Alnylam Pharmaceuticals Inc. $292.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157192
Principal investigator 1 Alnylam Pharmaceuticals Inc. $144.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157200
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157292
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157294
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,543.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157296
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157298
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,971.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157300
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157302
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157306
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157308
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157310
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,543.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157312
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,253.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157314
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121157316
Principal investigator 1 Janssen Pharmaceuticals, Inc $13,652.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938776
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156574
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156576
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156578
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156580
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156582
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156584
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156586
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156588
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156590
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156626
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156628
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156634
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156636
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156638
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156640
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156642
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156644
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156646
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156648
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156650
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156652
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156654
Principal investigator 1 ModernaTX, Inc. $38,819.35 03/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147140998
Principal investigator 1 PFIZER INC. $15,000.00 03/28/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131104479
Principal investigator 1 PFIZER INC. $5,000.00 03/28/2024 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131104485
Principal investigator 1 ModernaTX, Inc. $2,970.00 03/27/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147132453
Principal investigator 1 ModernaTX, Inc. $90,979.20 03/27/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147132603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 03/25/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156994
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,248.00 03/25/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156996
Principal investigator 1 Janssen Pharmaceuticals, Inc $21,624.00 03/25/2024 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938754
Principal investigator 1 ModernaTX, Inc. $25,172.59 03/21/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147140906
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 03/18/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156986
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,499.00 03/18/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121157008
Principal investigator 1 ModernaTX, Inc. $151,282.50 03/15/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147132559
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444848
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444854
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444860
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444868
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444970
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444976
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444984
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444988
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445130
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445132
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445134
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445136
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445138
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445140
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445142
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445144
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445146
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445148
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445150
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445152
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445154
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445156
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445158
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445160
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445162
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445164
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445166
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445168
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445170
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445172
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445174
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445176
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445178
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445180
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445182
Principal investigator 1 Seqirus USA Inc $50.60 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123445184
Principal investigator 1 Novavax Inc $39,963.00 03/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123376101
Principal investigator 1 Janssen Pharmaceuticals, Inc $89,454.00 03/13/2024 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938780
Principal investigator 1 ModernaTX, Inc. $81,072.38 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147132411
Principal investigator 1 ModernaTX, Inc. $87,318.87 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147132413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $146.00 03/06/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156962
Principal investigator 1 Alnylam Pharmaceuticals Inc. $72.00 03/06/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156964
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,667.22 03/05/2024 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089696615
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $320,765.80 03/02/2024 Non-covered Recipient Entity
Velocity Clinical Research Durham
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1101071869
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $286,148.60 03/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Durham
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1101071333
Principal investigator 1 ModernaTX, Inc. $12,739.16 03/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147132431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156656
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156658
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156660
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156662
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156664
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156666
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156762
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156764
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156766
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156768
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156770
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156772
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156774
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156776
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156778
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156780
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156782
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156784
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156786
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156788
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156790
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156792
Principal investigator 1 Novo Nordisk AS $442.44 02/29/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096780327
Principal investigator 1 ModernaTX, Inc. $550.00 02/28/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147132247
Principal investigator 1 ModernaTX, Inc. $40,904.07 02/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147140736
Principal investigator 1 Novo Nordisk AS $26,544.37 02/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1096849905
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,593.08 02/26/2024 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1101070931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,802.08 02/26/2024 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1101071867
Principal investigator 1 Novo Nordisk AS $1,000.00 02/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1096850308
Principal investigator 1 ModernaTX, Inc. $15,787.61 02/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147132375
Principal investigator 1 ModernaTX, Inc. $37,482.30 02/21/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147140716
Principal investigator 1 Novavax Inc $5,735.00 02/21/2024 Non-covered Recipient Entity
PREFERRED RESEARCH PARTNERS INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123374517
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,750.00 02/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110840938
Principal investigator 1 ModernaTX, Inc. $36,333.70 02/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147132125
Principal investigator 1 ModernaTX, Inc. $87,213.75 02/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147132191
Principal investigator 1 Eli Lilly and Company $60,181.00 02/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1137370532
Principal investigator 1 Novavax Inc $3,918.00 02/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults younger than 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1123375021
Principal investigator 1 Novavax Inc $300.00 02/07/2024 Non-covered Recipient Entity
SANDHILL RESEARCH LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123377209
Principal investigator 1 ModernaTX, Inc. $37,206.00 02/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147132249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156568
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156570
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156572
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156592
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156594
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156596
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156598
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156600
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156602
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156604
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156606
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156608
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156610
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156612
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156614
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156616
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156618
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156620
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156622
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156624
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156630
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156632
Principal investigator 1 Eli Lilly and Company $1,772.72 01/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1137370544
Principal investigator 1 Novo Nordisk AS $3,888.36 01/29/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1096815946
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,824.21 01/26/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 1110842608
Principal investigator 1 Eli Lilly and Company $9,264.70 01/26/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
AN OPEN-LABEL, SINGLE-ARM, PHASE 4 STUDY TO ASSESS GLYCEMIC CONTROL WHEN ADULTS WITH TYPE 2 DIABETES SWITCH FROM A GLP-1 RA TO TIRZEPATIDE (SURPASS-SWITCH-2) No dispute reported 06/30/2026 1137369712
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147131835
Principal investigator 1 ModernaTX, Inc. $1,800.00 01/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147131837
Principal investigator 1 ModernaTX, Inc. $9,516.00 01/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147131839
Principal investigator 1 ModernaTX, Inc. $87,435.00 01/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147131599
Principal investigator 1 ModernaTX, Inc. $67,324.44 01/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147140438
Principal investigator 1 Seqirus USA Inc $167.50 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123440600
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441998
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442004
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442006
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442012
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442026
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442032
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442046
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442048
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442052
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442415
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442429
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442447
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442467
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442469
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442477
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442489
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442493
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442505
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442511
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442819
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442821
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442823
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442825
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442827
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442829
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442831
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442833
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442835
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442837
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442839
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442841
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442843
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442845
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442847
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442849
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442851
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442853
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442855
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442857
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442859
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442861
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442863
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442865
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442867
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442869
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442871
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442873
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442875
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442877
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442879
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442881
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442883
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442885
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442887
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442889
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442891
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442893
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442895
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442897
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442899
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442901
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442903
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442905
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442907
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442909
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442911
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442913
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442915
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442917
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123442919
Principal investigator 1 GlaxoSmithKline, LLC. $16,943.72 01/10/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127525834
Principal investigator 1 Boehringer Ingelheim International GmbH $14,703.10 01/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1101068871
Principal investigator 1 Boehringer Ingelheim International GmbH $10,803.62 01/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1101068929